Cargando…

Nephrotoxicity in survivors of Wilms' tumours in the North of England

One aspect of concern for survivors of Wilms' tumour has been the late outcome in terms of renal function. Previous studies have documented low glomerular filtration rate and high blood pressure in some patients. Furthermore, disorders in tubular function (especially urinary concentration defec...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, S, Roberts, A, Brock, C, Price, L, Craft, A W, Kilkarni, R, Lee, R E J, Skillen, A W, Skinner, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376198/
https://www.ncbi.nlm.nih.gov/pubmed/12402147
http://dx.doi.org/10.1038/sj.bjc.6600608
_version_ 1782154713269010432
author Bailey, S
Roberts, A
Brock, C
Price, L
Craft, A W
Kilkarni, R
Lee, R E J
Skillen, A W
Skinner, R
author_facet Bailey, S
Roberts, A
Brock, C
Price, L
Craft, A W
Kilkarni, R
Lee, R E J
Skillen, A W
Skinner, R
author_sort Bailey, S
collection PubMed
description One aspect of concern for survivors of Wilms' tumour has been the late outcome in terms of renal function. Previous studies have documented low glomerular filtration rate and high blood pressure in some patients. Furthermore, disorders in tubular function (especially urinary concentration defects) have been suggested but not confirmed in small studies. The aim of this study was to determine the prevalence and nature of subclinical and overt glomerular, proximal and distal renal tubular toxicity in a population based cohort of survivors of Wilms' tumour. Forty patients (24 female) with a median age of 4.3 years (3 months–11.8 years) at diagnosis were studied. Median follow-up was 8.8 (range 0.06–27.5) years. Glomerular filtration rate was measured by (51)Cr-EDTA plasma clearance, proximal tubular function by electrolyte fractional excretions, urine excretion of low molecular weight proteins (retinol-binding protein) and renal tubular enzymes (alanine aminopeptidase; N-acetylglucosaminidase) and distal tubular function by the osmolality of the first two urines of the day on 3 consecutive days. Renal size (ultrasound) and blood pressure were also measured. Mean (range) glomerular filtration rate was 100 (61–150) ml min(−1) 1.73 m(−2). Nine were below the reference range for healthy individuals with two kidneys. Most serum electrolyte concentrations (sodium, potassium, chloride, calcium, magnesium and phosphate) fell within the normal range for age, as did the fractional excretions. The values that fell outside the normal range were only marginally abnormal. Subclinical measures of tubular toxicity (retinal-binding protein, alanine aminopeptidase, N-acetylglucosaminidase) were abnormal in only four patients. Thirty-seven patients achieved maximal urine osmolalities ⩾800 mOsm kg(−1), but three failed to achieve this value even after DDAVP administration. Two patients had evidence of increased urinary albumin excretion. Compensatory renal hypertrophy was seen in all but two patients, but blood pressure was within normal limits in all patients. Current and past treatment for Wilms' tumour does not have any clinically important nephrotoxic effect in the majority of patients. This finding will enable paediatric oncologists to reassure patients and parents that treatment for Wilms' tumour rarely causes long-term renal impairment. British Journal of Cancer (2002) 87, 1092–1098. doi:10.1038/sj.bjc.6600608 www.bjcancer.com © 2002 Cancer Research UK
format Text
id pubmed-2376198
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23761982009-09-10 Nephrotoxicity in survivors of Wilms' tumours in the North of England Bailey, S Roberts, A Brock, C Price, L Craft, A W Kilkarni, R Lee, R E J Skillen, A W Skinner, R Br J Cancer Clinical One aspect of concern for survivors of Wilms' tumour has been the late outcome in terms of renal function. Previous studies have documented low glomerular filtration rate and high blood pressure in some patients. Furthermore, disorders in tubular function (especially urinary concentration defects) have been suggested but not confirmed in small studies. The aim of this study was to determine the prevalence and nature of subclinical and overt glomerular, proximal and distal renal tubular toxicity in a population based cohort of survivors of Wilms' tumour. Forty patients (24 female) with a median age of 4.3 years (3 months–11.8 years) at diagnosis were studied. Median follow-up was 8.8 (range 0.06–27.5) years. Glomerular filtration rate was measured by (51)Cr-EDTA plasma clearance, proximal tubular function by electrolyte fractional excretions, urine excretion of low molecular weight proteins (retinol-binding protein) and renal tubular enzymes (alanine aminopeptidase; N-acetylglucosaminidase) and distal tubular function by the osmolality of the first two urines of the day on 3 consecutive days. Renal size (ultrasound) and blood pressure were also measured. Mean (range) glomerular filtration rate was 100 (61–150) ml min(−1) 1.73 m(−2). Nine were below the reference range for healthy individuals with two kidneys. Most serum electrolyte concentrations (sodium, potassium, chloride, calcium, magnesium and phosphate) fell within the normal range for age, as did the fractional excretions. The values that fell outside the normal range were only marginally abnormal. Subclinical measures of tubular toxicity (retinal-binding protein, alanine aminopeptidase, N-acetylglucosaminidase) were abnormal in only four patients. Thirty-seven patients achieved maximal urine osmolalities ⩾800 mOsm kg(−1), but three failed to achieve this value even after DDAVP administration. Two patients had evidence of increased urinary albumin excretion. Compensatory renal hypertrophy was seen in all but two patients, but blood pressure was within normal limits in all patients. Current and past treatment for Wilms' tumour does not have any clinically important nephrotoxic effect in the majority of patients. This finding will enable paediatric oncologists to reassure patients and parents that treatment for Wilms' tumour rarely causes long-term renal impairment. British Journal of Cancer (2002) 87, 1092–1098. doi:10.1038/sj.bjc.6600608 www.bjcancer.com © 2002 Cancer Research UK Nature Publishing Group 2002-11-04 2002-11-04 /pmc/articles/PMC2376198/ /pubmed/12402147 http://dx.doi.org/10.1038/sj.bjc.6600608 Text en Copyright © 2002 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
Bailey, S
Roberts, A
Brock, C
Price, L
Craft, A W
Kilkarni, R
Lee, R E J
Skillen, A W
Skinner, R
Nephrotoxicity in survivors of Wilms' tumours in the North of England
title Nephrotoxicity in survivors of Wilms' tumours in the North of England
title_full Nephrotoxicity in survivors of Wilms' tumours in the North of England
title_fullStr Nephrotoxicity in survivors of Wilms' tumours in the North of England
title_full_unstemmed Nephrotoxicity in survivors of Wilms' tumours in the North of England
title_short Nephrotoxicity in survivors of Wilms' tumours in the North of England
title_sort nephrotoxicity in survivors of wilms' tumours in the north of england
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376198/
https://www.ncbi.nlm.nih.gov/pubmed/12402147
http://dx.doi.org/10.1038/sj.bjc.6600608
work_keys_str_mv AT baileys nephrotoxicityinsurvivorsofwilmstumoursinthenorthofengland
AT robertsa nephrotoxicityinsurvivorsofwilmstumoursinthenorthofengland
AT brockc nephrotoxicityinsurvivorsofwilmstumoursinthenorthofengland
AT pricel nephrotoxicityinsurvivorsofwilmstumoursinthenorthofengland
AT craftaw nephrotoxicityinsurvivorsofwilmstumoursinthenorthofengland
AT kilkarnir nephrotoxicityinsurvivorsofwilmstumoursinthenorthofengland
AT leerej nephrotoxicityinsurvivorsofwilmstumoursinthenorthofengland
AT skillenaw nephrotoxicityinsurvivorsofwilmstumoursinthenorthofengland
AT skinnerr nephrotoxicityinsurvivorsofwilmstumoursinthenorthofengland